VivoSeq
Dermatology

Seborrheic Dermatitis

21

Pipeline Programs↗

2

Active Trials↗

14

Companies Involved↗

Seborrheic Dermatitis is an emerging landscape with 21 programs across 14 companies. The most active players are Sinomune Pharmaceutical Co., Ltd, Arcutis Biotherapeutics, Inc., LEO Pharma. 9 therapies are approved with 2 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

47/100

Pipeline Velocity

11/100

Mech. Concentration

50/100

Completion Rate

88/100

Attrition Rate

11/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

S

Sinomune Pharmaceutical Co., Ltd

1 program

Phase 1A

Arcutis Biotherapeutics, Inc.

2 programs

Phase 2LEO Pharma logo

LEO Pharma

1 program

Phase 2Bayer logo

Bayer

1 program

Phase 2Pfizer logo

Pfizer

1 program

Phase 2H

Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

2 programs

Phase 3

Pipeline

Programs by Phase

Analysis

Trial Status

19

clinical trials

Completed14 · 74%
Not yet recruiting2 · 11%
Terminated2 · 11%
Unknown status1 · 5%

Clinical Trials

Trial Activity

19 trials

ZYG24002 Lotion to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy in Adult Patients With Mild to Moderate Seborrheic Dermatitis
Not yet recruiting·SSinomune Pharmaceutical Co., Ltd·Phase 1·NCT07404033·48 enrolled
A Phase 3 Multicenter, Randomized, Parallel Group, Double Blind, Vehicle-controlled Study of the Efficacy and Safety of Roflumilast Foam 0.3% (ZORYVE®) in Trial Participants With Seborrheic Dermatitis
Not yet recruiting·HHangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.·Phase 3·NCT07683806·309 enrolled
Long-Term Safety of ARQ-154 Foam in Subjects With Seborrheic Dermatitis
Completed·AArcutis Biotherapeutics, Inc.·Phase 2·NCT04445987·408 enrolled
Seborrheic Dermatitis: Ketoconazole 2% Foam Versus Ketoconazole 2% Shampoo
Completed·SSt. Louis University·N/A·NCT01203189·23 enrolled
Tacrolimus Ointment Interest (PROTOPIC ®) in the Maintenance Treatment of Severe Seborrheic Dermatitis
Completed·UUniversity Hospital, Rouen·Phase 3·NCT02004860·120 enrolled
Trial of PDE4 Inhibition With Roflumilast (ARQ-154) Foam 0.3% for the Management of Seborrheic Dermatitis (STRATUM)
Completed·AArcutis Biotherapeutics, Inc.·Phase 3·NCT04973228·457 enrolled
Clobetasol Propionate 0.05% Shampoo in Association With Antifungal Shampoo in Scalp Seborrheic Dermatitis
Completed·GGalderma R&D·Phase 3·NCT00862654·326 enrolled
A Study of Azelaic Acid (AzA) 15% Gel in the Treatment of Seborrheic Dermatitis of the Face
Completed·LEO Pharma logoLEO Pharma·Phase 2·NCT00408330·48 enrolled
A 4 Week Study of Elidel (Pimecrolimus) for the Treatment of Seborrheic Dermatitis
Completed·DDermatology Specialists Research·Phase 2·NCT00403559·113 enrolled
Safety and Efficacy of ARQ-154 Foam in Subjects With Seborrheic Dermatitis
Completed·AArcutis Biotherapeutics, Inc.·Phase 2·NCT04091646·226 enrolled
Proactive Treatment of Tacrolimus Ointment for Adult Facial Seborrheic Dermatitis
Completed·PPusan National University Hospital·Phase 4·NCT01591070·104 enrolled
Safety and Efficacy Study in Subjects With Seborrheic Dermatitis
Completed·MMedicis Global Service Corporation·Phase 2·NCT01703793·240 enrolled
Pilot Study for the Use of Photodynamic Therapy in the Treatment of Seborrheic Dermatitis
Completed·UUniversity of California, Davis·Phase 1·NCT03114111·12 enrolled
A Study to Evaluate the Safety and Efficacy of PAC-14028 Cream in Seborrheic Dermatitis
Completed·AAmorepacific Corporation·Phase 2·NCT02749383·75 enrolled
A Proof of Concept Clinical Trial Evaluating the Safety and Efficacy of Eucrisa (Crisaborole) in Patients With Seborrheic Dermatitis
Completed·UUniversity of Alabama at Birmingham·Phase 4·NCT03567980·30 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)